论文部分内容阅读
2013年8月24日,中国工程院院士、第十一届全国人大常委会副委员长桑国卫就中国的药物创新战略以及中国制药企业的发展方向发表了自己的观点和意见。桑国卫院士首先介绍了我国生物医药产业的基本情况和在国民经济中的地位。他说,国家的政策导向是积极鼓励生物医药创新,从2007年首次进入国家的战略规划,到国家十二五规划纲要颁布,特别是国家十二五规划纲要明确指出,把生物医药作为战略性新兴产业使
On August 24, 2013, Sang Guowei, academician of the Chinese Academy of Engineering and vice chairman of the 11th NPC, expressed his opinions and opinions on China’s drug innovation strategy and the development direction of China’s pharmaceutical enterprises. Sang Guowei academicians first introduced the basic situation of China’s biomedical industry and its status in the national economy. He said that the state’s policy orientation is to actively encourage biomedical innovation, first entered the country’s strategic plan in 2007, and promulgated the 12th Five-Year Plan for the country. In particular, the 12th Five-Year Plan of the State explicitly states that biomedicine should be regarded as a strategic Emerging industries make